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ABSTRACT 
The Late-Breaking Clinical Trials presentations at the American College of Cardiology 
Scientific Sessions March 2018 are an important contribution to the field of cardiology. This 
article presents a constructive critical appraisal of seven key such studies: ODYSSEY, VEST, 
SECURE-PCI, TREAT, POISE, SMART-DATE and CVD REAL 2. For each one our aim is to 
document and interpret the main findings, noting particularly when “positive spin” appears to 
occur. Our aim is to provide a balanced account of each study, paying attention to both 
constructive new findings and study limitations. These topical examples also provide useful 
general insights on what to look for when critiquing clinical trial presentations and publications. 
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Condensed Abstract: 
The Late-Breaking Clinical Trials presentations at the American College of Cardiology 
Scientific Sessions March 2018 are an important contribution to the field of cardiology. This 
article presents a constructive critical appraisal of seven key such studies: ODYSSEY, VEST, 
SECURE-PCI, TREAT, POISE, SMART-DATE and CVD REAL 2. For each our aim is to 
document and interpret the main findings, noting particularly when “positive spin” appears to 
occur. Our aim is to provide a balanced account of each study, including both new findings and 
study limitations. These examples provide useful general insights on how to critique clinical trial 
presentations and publications. 
 
Abbreviations: 
CHD  Coronary heart disease 
DAPT  Dual antiplatelet therapy 
MACE  Major adverse cardiac events 
MI  Myocardial Infarction 
NSTEMI  non-ST-Elevation Myocardial Infarction 
oGLD  Other glucose lowering drugs 
PCI  Percutaneous coronary intervention 
SGLT2i  Sodium-glucose Cotransporter-2 Inhibitors 
STEMI  ST-Elevation Myocardial Infarction 
WCD  Wearable cardioverter defibrillator 
 
Study Acronyms 
ODYSSEY OUTCOMES: Evaluation of Cardiovascular Outcomes After an Acute Coronary 
Syndrome During Treatment With Alirocumab 
VEST: Vest Prevention of Early Sudden Death Trial and VEST Registry 
SECURE-PCI: Statins Evaluation in Coronary Procedures and Revascularization 
TREAT: Ticagrelor in Patients with ST-Elevation Myocardial Infarction treated with 
Pharmacological Thrombolysis trial 
POISE: PeriOperative ISchemic Evaluation trial 
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SMART-DATE:  6-month versus 12-month or longer dual antiplatelet therapy after percutaneous 
coronary intervention in patients with acute coronary syndrome: a randomised, open-label, non-
inferiority trial 
CVD-REAL 2: Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-
2 Inhibitors 
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Introduction 
Each year the American College of Cardiology (ACC) Scientific Sessions are a major 
forum for presentations of original findings across a broad spectrum of research activities in 
cardiology. Of particular interest are the Late-Breaking Clinical Trials sessions since they 
provide the latest pivotal evidence on both new and established treatment practices in cardiology. 
This year on March 10 to 12 there were 8 such sessions in which 37 such studies were 
presented. To review all these studies would be an immense task, and hence we have selected 7 
key presentations for us to provide a constructive critical appraisal. These were chosen as being 
1) of major clinical importance and 2) within our sphere of expertise. They are listed in the 
Central Illustration. 
For each study our aim is to place it in context, summarize the design, present the main 
findings and then provide a critical interpretation. We pay particular attention to the multiplicity 
of data available for presentation, and the consequent problems that arise e.g. in having multiple 
secondary endpoints or multiple subgroup analyses. Potential biases, e.g. in the one non-
randomized study we review, are assessed. 
There is a natural desire for trialists to wish to emphasize the more positive aspects of their study 
findings. This “positive spin” carries the risk that presentations may not provide a balanced 
account of the totality of evidence (1) . We point out instances when this appears to occur.  
Overall we hope this article provides a meaningful commentary on some of the most 
topical (and sometimes controversial) presentations at ACC 2018. 
ODYSSEY OUTCOMES Trial (2) 
Alirocumab in acute coronary syndrome 
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This trial recruited 18,924 patients who 1) had an ACS event 1 to 12 months ago, 2) were 
on high-intensity statin therapy and 3) had inadequate control of lipids e.g. LDL cholesterol ≥70 
mg/dl. Patients were randomized to alirocumab (a PCSK9 inhibitor) or placebo. The primary 
composite efficacy endpoint was coronary heart disease (CHD) death, non-fatal MI, fatal or non-
fatal ischaemic stroke or unstable angina requiring hospitalization. As is common practice, let's 
call this MACE (Major Adverse Cardiovascular Events). Median follow-up was 2.8 years. As 
expected, patients on alirocumab had a marked reduction in LDL-cholesterol compared to 
placebo: -62.7% at 4 months which attenuated slightly to -54.7% at 4 years.  
Results for the primary efficacy endpoint and its components are shown in the top half of 
Table 1. MACE had a highly significant 15% relative reduction (hazard ratio 0.85) with 95% 
confidence interval (CI) from 7% to 22% reduction, P=0.0003. All four components of MACE 
had fewer events on alirocumab compared with placebo, though for CHD death this was not 
significant. 
It is relevant to express this primary result on an absolute scale. There were 149 fewer 
patients with a MACE event on alirocumab, out of 9462 patients per arm followed for a median 
2.8 years. This translates into a reduction of 5.62 first MACE events per 1000 years of treatment 
with 95% CI 2.35 to 8.89 per 1000 patient years. This can be converted to a number needed to 
treat (NNT): to prevent one MACE event, one needs to treat 63 patients for a median of 2.8 years 
with 95% CI 41 to 141. This is helpful in elucidating whether an overall strategy of prescribing 
alirocumab to all eligible patients is sufficiently effective and in turn cost-effective. 
There are several important considerations here: 
1) We are confined to the trial’s inevitably limited follow up so cannot generalize to the effects 
of longer-term treatment. 
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2) The plot of cumulative MACE events over time by treatment group (Figure 1) reveals no 
separation of the curves out to 1 year. This significant treatment-time interaction (P=0.03) 
means all the benefit appears to kick in after one year’s treatment. This departure from 
proportional hazards calls into question whether a hazard ratio is the best overall summary of 
the treatment effect. 
3) This absolute benefit will vary from patient to patient: that is, higher risk patients are liable to 
have a higher absolute benefit. For instance, the 27% of patients who were over 65 had a 
MACE rate around 55% higher than the rest. We would encourage the authors to undertake 
appropriate multivariable analysis so patients can be stratified according to their risk status 
(3). This will help refine which patients benefit the most from alirocumab treatment. 
Now we turn to the main secondary endpoints (bottom half of Table 1), which are listed in a 
predefined order for hierarchical statistical testing (4). This is in order to keep the overall type-1 
error at 0.05. The first four on the list were all highly significant, but CHD death and CV death 
were not (P=0.38 and P=0.15 respectively). 
For all-cause death there is an observed 15% relative risk reduction (hazard ratio 0.85) 
with 95% CI from a 2% to a  27% reduction, P=0.026. But since this sits lower in the hierarchy 
of statistical testing it does not fit in the formal list of claims for treatment efficacy, within the 
bounds of strict type 1 error control. A counter-argument is that overall survival is clearly the 
most important matter for patients and hence merits special attention beyond statistical 
formalities. A weakness in this statement is that the all-cause death finding rests on combining 
non-significant reductions in both CV deaths and non CV deaths (31 and 27 fewer deaths 
respectively) and the latter has no obvious rationale.  
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The next concern is over the interpretation of subgroup analyses for the primary MACE 
outcome. For the five main pre-specified subgroups, there were no statistically significant 
interactions with treatment. This would normally be the end of the matter: insufficient evidence 
that there are any identifiable effect-modifiers. But in this case, the idea is pursued that 
alirocumab may be more effective in the 30% of patients who had baseline LDL- cholesterol 
greater than or equal to 100 mg/dl: the observed relative risk reduction becomes 24% (95% CI 
13% to 35%), but it is questionable whether post hoc emphasis on this finding is justifiable (5,6) 
.  
Even more doubtful is the claim that all-cause mortality is reduced by 29% (with 95% CI 
10% to 44%) in patients with LDL-cholesterol greater than or equal to 100 mg/dl. Such data 
dredging amongst subgroup analyses for a secondary endpoint has little merit. 
Lastly, it is interesting to compare the main ODYSSEY findings with those of the 
FOURIER trial of evolocumab (7), another PCSK9 inhibitor. The two study populations are 
different: FOURIER focused on patients with a history of myocardial infarction, non-
hemorrhagic stroke or peripheral artery disease. Nevertheless, some consistency of findings 
emerge. Both trials show that a PCSK9 inhibitor reduces the risk of myocardial infarction and 
ischemic stroke. Also, neither trial shows an effect on cardiovascular death. Inconsistencies are 
that ODYSSEY shows apparent reductions in both unstable angina and in all cause death 
whereas FOURIER does not. This weakens yet further the claim that alirocumab reduces 
mortality in ACS patients. 
VEST EARLY PREVENTION OF SUDDEN DEATH trial (VEST) (8) 
Wearable Cardioverter Defibrillator (WCD) in post-MI patients 
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The hypothesis posed for this trial is: can a WCD reduce the risk of sudden death in the 
immediate post-MI period (up to 90 days) in patients with reduced ejection fraction (EF). The 
trial recruited 2309 patients within 7 days of hospital discharge after acute MI who had EF 
≤35%. They were randomized in a 2:1 ratio to WCD + guideline treatment (N=1,524) versus 
guideline treatment only (N=778) and then followed for 90 days. 
Results for the primary outcome (sudden death) and several pre-defined fatal and non-
fatal secondary outcomes are shown in Table 2. There is not a significant reduction in sudden 
death (P=0.18) and hence some have called this a “negative“ trial. This we find too dismissive 
since the observed difference in incidence of sudden death (1.6% versus 2.4%) is in favour of 
WCD: a 32.8% relative reduction but with a wide 95% CI ranging from a 21.2% increase to a 
62.8% decrease. A better term is to call the trial “inconclusive”. 
The problem is that the trial only has good statistical power to detect very marked 
treatment differences. For instance, had the total of 44 sudden deaths split 22 (1.4%) on WCD 
and 22 (2.8%) on control, then this hypothetical 50% risk reduction would have been significant 
with P=0.02. 
Even if the trial had been twice as big (N=4604 patients) the observed 32.8% reduction 
would still only have P=0.06. It would require three times as many patients (N=6906) for such a 
risk reduction to achieve P=0.02. 
This is the dilemma we face when undertaking trials of an intervention strategy (9), such 
as wearing a WCD in the VEST trial. Patient recruitment is much harder than in drug trials (in 
VEST it took almost 10 years to recruit 2302 patients) so that definitive evidence of efficacy is 
much harder to achieve.  
9 
A further issue is how well did patients comply with wearing the WCD; this averaged 
around 18 hours per day initially and declined to around 12 hours per day by 90 days (including 
non-users). Such reduced compliance over time must inevitably compromise the ability to 
prevent sudden deaths. 
Among the pre-defined secondary outcomes (Table 2) the one that really matters is all-
cause death with 90-day incidence of 3.1% on WCD versus 4.9% on control. This is a 35.5% 
relative risk reduction with 95% CI from 2.2% to 57.5% reduction, P=0.04. 
It is a natural instinct to now label VEST as a “positive” trial. After all, surely a significant result 
for all-cause death justifies such a claim?! But a more cautious interpretation is warranted. First, 
the result is statistically fragile: if there had been just one less death in the control arm, P 
becomes >0.05. Second, all-cause death is not the primary outcome. Third, it seems illogical that 
the WCD is equally effective in preventing both sudden- and non-sudden deaths. Thus, while it 
plausible that a WCD really does reduce mortality, the VEST trial’s evidence is not sufficiently 
convincing by itself. 
SECURE-PCI Trial (10) 
Loading dose of atorvastatin prior to planned PCI 
This double-blind trial randomized 4191 patients with ACS who had an angiogram with the 
intention of planned PCI to either 280 mg loading doses of atorvastatin or matching placebo. All 
patients subsequently received 40 mg atorvastatin daily for 30 days. The primary MACE 
outcome was a composite of all-cause death, myocardial infarction, stroke and unplanned 
coronary revascularization through 30 days. 
Table 3 shows the results for the primary outcome and its components. While there were 
numerically fewer primary events in the atorvastatin arm 130/2087 (6.2%) versus 149/2104 
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(7.1%) in the placebo arm, this did not achieve statistical significance: hazard ratio 0.88 with 
95% CI 0.69 to 1.11, P=0.27. 
Similarly, none of the components of the primary outcome showed a significant treatment 
effect. 
However, this apparently “negative” primary result should not be interpreted as proof that 
loading doses of atorvastatin have no effect (11). The confidence interval extends out to a 31% 
risk reduction, and such uncertainty means that a type 2 error (a false negative) is possible. In 
addition, the fact that patients in both arms got 40 mg atorvastatin for 30 days may have diluted 
any effect of the loading doses per se. 
Amongst several exploratory subgroup analyses there was no evidence of statistical 
interactions, except when comparing those who did or not undergo PCI (interaction P=0.02), see 
bottom of Table 3 and Figure 2. For those 65% of patients who actually underwent PCI the 
hazard ratio is 0.72 (95% CI 0.54 to 0.96) subgroup P=0.02 whereas for the rest the apparent 
treatment effect is in the opposite direction: hazard ratio 1.36 (95% CI 0.89 to 2.09) subgroup 
P=0.15. The latter is a curious finding since it is counter-intuitive (perhaps due to chance): it is 
hard to imagine how loading doses of atorvastatin could increase cardiovascular risk in patients 
not undergoing PCI. 
The subgroup claim that loading doses of atorvastatin substantially reduce the risk of MACE 
in patients actually undergoing PCI requires a cautious interpretation for the following reasons: 
1) In any trial, post hoc emphasis on the most positive of several subgroup analyses tends to 
lead to an exaggeration of the true treatment effect. 
2) The significant interaction (P=0.02) is reached because the observed effect for the non-PCI 
subgroup is in the opposite direction. Such qualitative interactions are inherently implausible. 
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3) The subgroup of patients undergoing PCI is an improper subgroup (12,13) in the sense that it 
was not known at the time of randomization. Patient factors determining who got PCI (or 
who did not) may have affected the outcome: in extreme a few patients may have had a very 
early MACE event before PCI could begin. 
4) This subgroup finding is of little practical value, since for future patients the decision 
whether to give loading doses of atorvastatin needs to be taken before one knows whether the 
patient will actually undergo PCI. In the trial 35% of patients did not undergo PCI. 
The perils of subgroup analyses are further illustrated when one does separate PCI/no PCI 
comparisons for STEMI and NSTEMI patients, see bottom part of Figure 2. For STEMI patients 
there is a significant interaction (P=0.04) whereas for NSTEMI patients there is not. At face 
value, this implies that the benefits of loading doses of atorvastatin are primarily confined to 
STEMI patients undergoing PCI. But commonsense suggests this arises from data dredging 
across multiple possible sub-group analyses and should not be taken seriously. 
TREAT study (14) 
Ticagrelor vs Clopidogrel after Fibrinolytic Therapy 
Worldwide many STEMI patients receive fibrinolytic therapy rather than primary PCI, and 
hence there is a need to evaluate the relative safety and efficacy of different antiplatelet regimens 
in this context. In this open-label trial 3799 such patients were randomized to either ticagrelor 
(180 mg loading dose, 90 mg twice daily thereafter) or clopidogrel (300 mg or 600 mg loading 
dose, 75 mg daily thereafter). Median time from fibrinolysis to randomization was 11.4 hours, 
and 90% were pre-treaded with clopidogrel. 
The primary outcome was TIMI major bleeding through 30 days. Secondary safety 
outcomes used other bleeding criteria. Also exploratory efficacy outcomes include the composite 
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of cardiovascular (CV) death, myocardial infarction (MI) and stroke. Results for the main safety 
and efficacy outcomes at 30 days follow-up are in Table 4. 
The primary outcome TIMI major bleed occurred in 0.73% and 0.69% of ticagrelor and 
clopidogrel patients respectively, a difference of +0.04% with 95% CI from -0.49% to +0.58%. 
There was a pre-defined non-inferiority hypothesis with an absolute margin of +1.0%. Since the 
95% CI excludes +1.0% a claim of non-inferiority of ticagrelor relative to clopidogrel can be 
made as regards TIMI major bleed. Similar conclusions can be made regarding the PLATO and 
BARC major bleeding criteria. However, for all bleeds there was a significant excess on 
ticagrelor compared with clopidogrel: absolute difference +1.57% with 95% CI +0.24% to 
+2.90%, P=0.02. The composite efficacy outcomes of CV death, MI and stroke had a similar 
incidence in both groups (4.0% ticagrelor, 4.3% clopidogrel P=0.57) and both groups had 49 
(2.6%) deaths from all causes within 30 days. 
With the proviso that ticagrelor had more minor bleeds, a conclusion that ticagrelor appears 
as good as clopidogrel in these patients seems appropriate. But a few outstanding issues remain: 
1) This is a relatively young low-risk population of STEMI patients (e.g. age over 75 was 
excluded), and so the incidence of major bleeding is low. 
2) The practical merit of demonstrating that ticagrelor is non-inferior to clopidogrel is open to 
debate, given the former is more expensive and the latter is more widely established. 
3) Was the delayed timing of ticagrelor administration in this trial making the most of its 
potential? An alternative trial could have explored the relative safety and efficacy of 
ticagrelor given alongside fibrinolytic therapy. 
POISE trial 
Metoprolol in patients undergoing non-cardiac surgery 
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Whether beta-blockers are of benefit in patients undergoing non-cardiac surgery is a 
controversial and unresolved topic. Previous positive recommendations in both US and European 
guidelines were shaken when it was found that the key DECREASE studies were fundamentally 
flawed (15). The latest ESC/ESA guidelines (16) take a more cautious position and conclude "a 
high priority needs to be given to new randomised clinical trials to better identify which patients 
derive benefit from blocker therapy in the perioperative setting, and to determine the optimal 
method of beta blockade. 
The POISE trial's previously published findings (17) on the short-term outcomes 
following extended-release metoprolol use alerted everyone to potential harms. The latest 
findings on one-year outcome are therefore of considerable interest. 
POISE randomised 8351 patients with, or at risk of, atherosclerotic disease who were undergoing 
non-cardiac surgery to receive extended-release metoprolol or placebo, starting two to four hours 
before surgery and continuing for 30 days. 
Table 5 presents results for the key outcomes for both 30 days follow up (previously reported) 
and 1-year follow-up (new).  
The main benefit of extended metoprolol is a highly significant reduction in the incidence 
of MI: 63 fewer at 30 days (P=0.0017) which attenuated slightly to 52 fewer at 1 year (P=0.008). 
The absolute one-year reduction in incidence of MI (metoprolol vs placebo) is 1.24% with 95% 
confidence interval 0.26% to 2.23%. 
In contrast, there is a significant excess of strokes on metoprolol: 22 more at 30 days (P=0.0053), 
and 26 more at 1 year (P=0.0014). The absolute one year increase in incidence of stroke is 
+0.62% with 95% CI 0.07% to 1.18%.  
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There is also a significant mortality excess on metoprolol: 32 more deaths at 30 days 
(P=0.032) which increases to 54 more deaths at one year (P=0.036). This is mainly driven by an 
excess of non-CV deaths (39 more on metoprolol, P=0.043), but there are also 15 more CV 
deaths on metoprolol, P=0.37. Overall, the absolute one year increase in mortality is +1.30% 
with 95% CI 0.06% to 2.54%. 
The overall picture is that metoprolol appears to do more harm than good, the risks of 
death and stroke outweighing the benefits of fewer myocardial infarctions and coronary 
revascularizations. It has been suggested that this problem arose because the chosen dose 
regimen (based on 100mg oral extended-release metoprolol initially) was too high. 
Whether there exists a more judicious choice of beta-blocker and dose regimen which can still be 
of benefit to appropriate patients undergoing non-cardiac surgery is an open question, which is 
only answerable by further large-scale randomised trials. As far as we know, no such trials are 
currently taking place. 
SMART-DATE trial (17) 
6 months versus 12+ months DAPT after PCI in ACS patients. 
There is an extensive literature dedicated to determining the optimal duration of dual antiplatelet 
therapy (DAPT) after drug eluting stent (DES) implantation (18). In general a longer DAPT 
duration is liable to reduce the incidence of ischaemic events but is accompanied an increased 
risk of bleeding complications.  
SMART-DATE (17) is the most recent trial to tackle this issue. A total of 2712 ACS 
patients undergoing PCI (99% got a DES) were randomised to either 6 months DAPT or 12 
months or longer DAPT. The primary MACE endpoint was a composite of all-cause death, MI, 
or stroke at 18 months after PCI in the intention-to-treat population.  
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Results for the primary and predefined secondary endpoints are shown in Table 6. Let us first 
focus on the MACE primary endpoint which occurred in 63 (4.7%) and 56 (4.2%) patients in the 
6-month DAPT group and 12-month DAPT group respectively. The trial primary hypothesis was 
non-inferiority of the former relative to the latter with a predefined margin of 2%. The observed 
difference is 0.5% with an upper one-sided 95% CI of 1.8%. Thus, formally the claim of non-
inferiority is established.  
However, several concerns exist regarding the interpretation of such a non-inferiority trial (19) 
1) It is useful to calculate a two-sided 95% CI which in this case is from -0.05% to +2.05%. 
This corresponds to a one-sided Type-I error of 2.5% (rather than 5%) as is often done in 
non-inferiority trials. On this basis the CI includes the 2.0% margin and makes the trial 
inconclusive regarding non-inferiority 
2) A 2% margin is very wide, and with a 4.5% MACE rate being anticipated is equivalent to a 
margin of 1.44 on a ratio scale i.e. ruling out such a 44% excess of events would not really 
be convincing. 
3) Since everyone gets DAPT for the first six months, only MACE events occurring after 6 
months are really relevant to the treatment comparison. This landmark analysis, which 
necessarily excludes patients having an event before 6 months, is shown in Figure 3. The 
MACE rate is now somewhat higher in the 6-month DAPT group: hazard ratio 1.69 (95% CI 
0.97 to 2.94), P=0.07. The CI is very wide since the numbers of MACE events between 6 
months and 18 months (not given) are relatively small. We are now getting close to 
significant inferiority of the 6-month DAPT arm, and any claim of non-inferiority is clearly 
ruled out.  
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Among the secondary endpoints in Table 6, prior trials and meta-analyses suggest it is wise to 
focus on MI, stent thrombosis and bleeding events. Here the 6-month DAPT group has 14 more 
MIs and 5 more stent thromboses than the 12 months DAPT group. This is counterbalanced by 
the former having 16 fewer BARC 2-5 bleeds and four fewer major bleeds. However, this is hard 
to interpret sensibly because of comment 3) above, i.e. the numbers include events before 6 
months when the two groups were on identical DAPT treatment. 
The meta-analysis by Giustino et al (18) based on 10 randomised trials and 32,215 
patients estimated that a shorter duration significantly increased the risk of stent thrombosis 
(odds ratio 1.71, P=0.001) and myocardial infarction (odds ratio 1.39, P<0.001) and reduced the 
risk of clinically significant bleeding (odds ratio 0.63, P<0.001), and may reduce the mortality 
risk (odds ratio 0.87, P=0.07). Put more simply, with around 16,000 patients in each group 
shorter DAPT duration resulted in 111 more MIs, 63 more stent thromboses, 118 fewer clinically 
significant bleeds and 49 fewer deaths. Of course any meta-analysis has the potential to 
oversimplify findings from a heterogeneous mix of studies (e.g. the risk of stent thrombosis is 
lower in second generation DES), but only through combining evidence across all relevant trials 
can one reach robust conclusions on this issue. 
While SMART-DATE appears a well conducted trial which can usefully contribute to 
future meta-analyses, it has too few patients and events to reach meaningful conclusions in its 
own right regarding the trade-off between poorer efficacy and improved safety by reducing the 
duration of DAPT. 
CVD-REAL 2 study (20) 
Comparative effectiveness of SGLT2 inhibitors for cardiovascular outcomes 
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This study examines whether initiation of SGLT2 inhibitors is associated with a lower risk of CV 
events compared with other glucose lowering drugs (oGLD) using “real world” data for over 
400,000 patients with type 2 diabetes in three world regions. Before describing and interpreting 
the findings, it is relevant to make some general remarks on the pros and cons of this type of 
comparative effectiveness study. 
The good news is that such studies can give access to very large numbers of patients 
because they use data from medical claims, primary care/hospital records and national registries. 
This facilitates more precise estimates of associations between treatments and patient outcomes 
than is possible in randomised trials which are inevitably of limited size. Secondly they reflect 
the "real world" practice of medicine unconstrained by the strict eligibility criteria of randomised 
controlled trials (RCTs). Thus, they have an aura of greater generalisability than in RCTs.  
The bad news is that the so called "real world" is a "messy place" from the perspective of 
seeking robust, unbiased treatment comparisons (21-23). The biggest problem is the selection 
process that determines which treatment gets given to each patient. Without randomisation there 
is always a risk that patients on any given drug (or class of drug) have an underlying better 
average prognosis than others. One tries to correct for this by adjusting for known patient 
characteristics using propensity score methods, but the presence of residual confounding and 
hence bias in the results always remains a real possibility. Another limitation of “real world” data 
is that it is collected in a less reliable manner: both baseline features and patient outcomes are 
left to the discretion of each practicing physician e.g. for non-fatal events (e.g. myocardial 
infarction) and causes of death, robustness of definitions and centralised adjudication are lacking. 
So now to the results of the CVD-REAL (24) and CVD-REAL2 study (20). The first 
study in 6 countries identified 166,033 eligible new users of an SGLT2i and 1,226,221 eligible 
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new users of oGLD. In every country the former tended to be younger, with less established 
CVD, less CKD and less frail. The second study CVD-REAL 2 includes 249,348 SGLT2i and 
3,668,203 oGLD patients from a further six countries. This time the former tended to be 
younger, with less CKD, less frail, more on metformin and on statin and recruited more recently. 
To correct for these imbalances and other patient characteristics, propensity-matched pairs of 
patients were extracted leading to 235,064 patients for analysis in each group. In CVD-REAL 2 
the SGLT2i use was 75% dapaglifozin, 9% empagliflozin and 12% others.  
The main results of CVD-REAL 2 are in Figure 4. They show that overall, patients on 
SGLT2i have a lower risk of all-cause death (HR 0.51, 95% CI 0.37 to 0.70), hospitalization for 
heart failure (HR 0.64, 95% CI 0.50 to 0.82), myocardial infarction (HR 0.81, 95% CI 0.74 to 
0.88) and stroke (HR 0.68, 95% CI 0.55 to 0.84). All four associations are highly significant, but 
the first three also show highly significant heterogeneity between countries, e.g. the associations 
were weaker in Korea, which contributed over 70% of patients.  
There are two problems here. First, the random-effects meta-analysis used tends to 
weight countries with fewer patients more than is appropriate (25,26), e.g. the biggest apparent 
heart failure effect in Canada pulls the overall effect in a more positive direction. A fixed-effect 
meta-analysis would lead to more modest overall treatment differences for death, heart failure 
and stroke since it gives more weight to the largest country Korea which had much smaller 
treatment differences. Second, one suspects the heterogeneity across countries is more about 
their differing selection biases rather than genuine geographic variations in treatment effects. 
These findings need to be seen in the context of key randomised trials of SGLT2is, 
namely EMPA-REG (27) and CANVAS (28). Both showed reductions in heart failure 
hospitalization compared to placebo, consistent with what CVD-REAL 2 shows. For myocardial 
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infarction and stroke the trials showed no significant benefit of SGLT2is which casts doubt on 
the causal validity of such associations in CVD-REAL 2. For all-cause death the overall claim of 
a 49% reduction in hazard seems liable to be an exaggeration, the 28% reduction in Korea seems 
plausible, given the known mortality reduction in EMPA-REG, but not in CANVAS. 
Since dapagliflozin contributes most SGLT2i patients to this study, we clearly need to 
wait for the DECLARE trial (29,30) results before casting a final verdict on the believability of 
these findings in CVD-REAL 2. As always such observational studies can only study 
associations: whether they depict genuine beneficial treatment effects can only be established 
through evidence from randomised controlled trials.  
DISCUSSION 
In the process of reviewing these 7 late breaking clinical trials, we find some general 
issues worthy of comment. First, presentations of new evidence at major scientific meetings such 
as ACC are not peer reviewed. Hence the presenters and their collaborators have essentially a 
free rein to present their study findings as they see fit. Given they have often devoted years of 
effort in conducting a major trial there is a natural wish to present their findings “in a good 
light”. On the whole, presenters of major studies are top-level highly-respected scientists for 
whom the quest for truth is paramount. Nevertheless, at the key moment of first presentation of 
pivotal findings it is only human nature to allow a degree of “positive spin” to creep in (1). This 
same temptation may also be felt by study sponsors, whether commercial or public bodies. In our 
Central Illustration the last two columns summarize how this may have occurred in these 7 
specific presentations.  
Second, a conference presentation is just the first step in the release and interpretation of 
study findings. The first peer-reviewed publication in a major medical journal is what matters in 
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the long run. Indeed 4 of the 7 studies we have reviewed had simultaneous publications. Given 
the high standards set by journal editors and reviewers and use of CONSORT guidelines (31), 
such publications are less prone to “positive spin”: the conclusions usually focus on the 
predefined primary outcome in the whole trial population, with other possible claims on 
secondary endpoints and subgroup analyses referred to as exploratory findings. Sometimes this 
practice seems a little too restrictive, as if any ideas after database lock can have no bearing on 
what should be future clinical practice. But there is a fine line to be drawn between flexibility (let 
all the data speak) and selectivity (how can I make my trial more “positive”?). 
Of course, journal publications are of finite size and are often written quickly to meet 
conference deadlines, so they in turn do not necessarily provide the “whole truth”. For drug or 
device trials much more detailed regulatory dossier get presented to the FDA, EMA and other 
agencies. That is where the final detailed totality of evidence gets judged.  
But the importance and excitement of a first conference presentation is hard to overstate. 
Thus, we greatly appreciate this opportunity to review some of the key trials of ACC 2018, and 
hope our insights are a stimulus to further discussion on what they each mean for future best 
clinical practice. 
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Table 1: Primary and Secondary Efficacy Endpoints in the ODYSSEY OUTCOMES Trial 
Endpoint, n (%) 
Alirocumab 
(N=9462) 
Placebo  
(N=9462) 
HR (95% CI) 
Log-rank 
P-value 
MACE  903 (9.5)  1052 (11.1)  0.85 (0.78, 0.93)  0.0003 
CHD death  205 (2.2)  222 (2.3)  0.92 (0.76, 1.11)  0.38 
Non-fatal MI  626 (6.6)  722 (7.6)  0.86 (0.77, 0.96)  0.006 
Ischemic stroke  111 (1.2)  152 (1.6)  0.73 (0.57, 0.93)  0.01 
Unstable angina  37 (0.4)  60 (0.6)  0.61 (0.41, 0.92)  0.02 
     
CHD event  1199 (12.7)  1349 (14.3)  0.88 (0.81, 0.95)  0.001 
Major CHD event  793 (8.4)  899 (9.5)  0.88 (0.80, 0.96)  0.006 
CV event  1301 (13.7)  1474 (15.6)  0.87 (0.81, 0.94)  0.0003 
Death, MI, ischemic stroke  973 (10.3)  1126 (11.9)  0.86 (0.79, 0.93)  0.0003 
CHD death  205 (2.2)  222 (2.3)  0.92 (0.76, 1.11)  0.38 
CV death  240 (2.5)  271 (2.9)  0.88 (0.74, 1.05)  0.15 
All-cause death  334 (3.5)  392 (4.1)  0.85 (0.73, 0.98)  0.026* 
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Table 2: Results of the VEST trial over 90 days of follow-up 
Clinical event type 
WCD  
(N=1524) 
Control  
(N=778) 
P-value 
FATAL EVENTS, n (%)      
Sudden Death (primary outcome)  25 (1.6%)  19 (2.4%)  0.18 
Non-sudden death  21 (1.4%)  17 (2.2%)  0.15 
Congestive heart failure death  10 (0.7%)  5 (0.6%)  1.00 
Recurrent MI death  1 (0.1%)  1 (0.1%)  1.00 
Stroke death  0 (0.0%)  4 (0.5%)  0.01 
Other cardiovascular death  5 (0.3%)  3 (0.4%)  1.00 
Other death  5 (0.3%)  4 (0.5%)  0.72 
Indeterminate death  2 (0.1%)  2 (0.3%)  0.83 
Death, any cause  48 (3.1%)  38 (4.9%)  0.04 
NON-FATAL EVENTS, n (%)     
Rehospitalization, cardiovascular  334 (22%)  174 (22%)  0.81 
Rehospitalization, any cause  475 (31%)  253 (33%)  0.51 
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Table 3: 30 Day Outcomes Overall and in Patients Undergoing and Not Undergoing PCI in 
the SECURE-PCI trial 
 
  No. /Total No. (%)   Absolute Difference, Hazard Ratio  
Outcomes  Atorvastatin    Placebo   % (95% CI) (95% CI) P value 
Primary Outcome at 30 d        
MACE    130/2087 (6.2)    149/2104 (7.1)    0.85 (−0.70 to 2.41)    0.88 (0.69-1.11)    .27   
 Components of Primary Outcome at 30 d          
 Death    67/2087 (3.2)    70/2104 (3.3)    0.12 (−1.01 to 1.24)    0.97 (0.69-1.35)    .84   
 Cardiovascular death    59/2087 (2.8)    61/2104 (2.9)    0.07 (−0.99 to 1.13)    0.98 (0.68-1.40)    .90   
 Myocardial infarction    61/2087 (2.9)    77/2104 (3.7)    0.74 (−0.39 to 1.86)    0.80 (0.57-1.11)    .18   
 Peri-PCI    42/2087 (2.0)    54/2104 (2.6)    0.55 (−0.40 to 1.51)    0.78 (0.52-1.17)    .23   
 Non–PCI-related    20/2087 (1.0)    26/2104 (1.2)    0.28 (−0.40 to 0.96)    0.77 (0.43-1.39)    .39   
 Coronary revascularization    11/2087 (0.5)    14/2104 (0.7)    0.14 (−0.38 to 0.65)    0.79 (0.36-1.75)    .57   
 Urgent or target vessel    5/2087 (0.2)    9/2104 (0.4)    0.19 (−0.21 to 0.58)    0.56 (0.19-1.67)    .30   
 Stroke    10/2087 (0.5)    11/2104 (0.5)    0.04 (−0.43 to 0.51)    0.92 (0.39-2.16)    .85   
 Stent thrombosis    7/2087 (0.3)    15/2104 (0.7)    0.38 (−0.11 to 0.86)    0.47 (0.19-1.15)    .10   
      
Exploratory Analysis of 30 day MACE in Subgroup of  
Patients Undergoing and Not Undergoing PCI 
PCI  81/1351 (6.0)    112/1359 (8.2)    2.25 (0.24 to 4.25)    0.72 (0.54-0.96)    .02   
No PCI  49/734 (6.7)    37/743 (5.0)    −1.70 (−4.22 to 0.83)    1.36 (0.89-2.09)    .15   
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Table 4: Main Safety and Efficacy Outcomes at 30 days in the TREAT study 
 No. (%)  
 Ticagrelor 
(n = 1913) 
Clopidogrel 
(n = 1886) 
Absolute Difference, % 
(95% CI) 
Safety Outcomes      
TIMI major bleeding   14 (0.73) 13 (0.69) 0.04 (-0.49 to 0.58) 
PLATO major bleeding   23 (1.20) 26 (1.38) -0.18 (-0.89 to 0.54) 
BARC type 3-5 bleeding   23 (1.20) 26 (1.38) -0.18 (-0.89 to 0.54) 
Any bleeding 103 (5.38) 72 (3.82) 1.57 (0.24 to 2.90) 
      
Efficacy Outcomes      
CV death, MI, or stroke 76 (3.97) 82 (4.35) -0.38 (-1.65 to 0.90) 
All-cause death 49 (2.56) 49 (2.60) -0.04 (-1.04 to 0.97) 
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Table 5: Results for key fatal and non-fatal outcomes in the POISE trial for both 30 day 
and 1 year follow-up.  
 30 days  1 year + 
 
Metoprolol 
[N=4174] 
Placebo 
[N=4177] 
  
Metoprolol 
[N=4174] 
Placebo 
[N=4177] 
 
CV death, MI or stroke* 244 290 P=0.040     
        
MI 176 239 P=0.0017  208 260 P=0.008 
Cardiac Revascularisation 11 27 P=0.012  21 45 P=0.004 
Stroke 41 19 P=0.0053  85 59 P=0.014 
        
All-cause death 129 97 P=0.032  410 356 P=0.036 
CV death 75 58 P=0.14  182 167 P=0.37 
Non-CV death 54 39 P=0.12  228 189 P=0.043 
        
* The pre-defined primary composite outcome at 30 days. 
+ One-year follow-up was achieved in around 90% of patients 
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Table 6: Clinical primary and secondary outcomes at 18 months in the SMART-DATE 
trial 
 
 
6-month 
DAPT group 
(n=1357) 
12-month or 
longer DAPT 
group (n=1355) 
HR (95% CI) 
p 
value 
MACE (primary) 63 (4·7%) 56 (4·2%) 1·13 (0·79–1·62) 0·51  
     
Death  35 (2·6%) 39 (2·9%) 0·90 (0·57–1·42) 0·90  
Myocardial infarction: total 24 (1·8%) 10 (0·8%) 2·41 (1·15–5·05) 0·02  
Target vessel MI 14 (1·1%) 7 (0·5%) 2·01 (0·81–4·97) 0·13  
Non-target vessel MI 10 (0·8%) 3 (0·2%) 3·35 (0·92–12·18) 0·07  
Stroke 11 (0·8%) 12 (0·9%) 0·92 (0·41–2·08) 0·84  
Cardiac death  18 (1·4%) 24 (1·8%) 0·75 (0·41–1·38) 0·36  
Cardiac death or myocardial infarction  39 (2·9%) 32 (2·4%) 1·22 (0·77–1·95) 0·40  
Stent thrombosis  15 (1·1%) 10 (0·7%) 1·50 (0·68–3·35) 0·32  
BARC type 2–5 bleeding  35 (2·7%) 51 (3·9%) 0·69 (0·45–1·05) 0·09  
Major bleeding  6 (0·5%) 10 (0·8%) 0·60 (0·22–1·65) 0·33  
Net adverse clinical and cerebral events*  96 (7·2%) 99 (7·4%) 0·97 (0·73–1·29) 0·84  
 
Percentages are Kaplan-Meier estimates. We defined MACE as a composite of all-cause mortality, myocardial 
infarction, and stroke. HR=hazard ratio. BARC=Bleeding Academic Research Consortium. *Net adverse clinical and 
cerebral events were defined as MACE plus BARC type 2–5 bleeding. 
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Central Illustration: 7  Key Studies in ACC Late-Breaking Sessions 
study treatments patients main finding positive spin caution 
ODYSSEY 
alirocumab  
vs 
placebo 
ACS 
15% reduction in MACE 
P=0.0003 
29% mortality reduction 
for LDL≥100mg/dl 
post hoc subgroup 
in secondary endpoint 
no significant interaction 
 
VEST 
wearable cardioverter 
defibrillator  
vs  
control 
post-MI  
with EF≤35% 
no significant reduction 
in sudden death 
35.5% mortality reduction 
P=0.04 
secondary endpoint 
underpowered 
SECURE-PCI 
atorvastatin loading dose 
vs 
placebo 
ACS with  
planned PCI 
no significant reduction 
in MACE 
38% MACE reduction 
after undergoing PCI 
P=0.02 
an improper  
subgroup analysis 
TREAT 
ticagrelor 
vs 
clopidogrel 
STEMI patients 
after fibrinolysis 
no treatment 
differences 
ticagrelor non-inferior  
re major bleed 
a claim of little 
 practical value? 
POISE 
metoprolol 
vs 
placebo 
non-cardiac surgery 
at high CV risk 
1.3% excess  
1-year mortality  
P=0.032 
none 
metoprolol dose 
too high? 
SMART-DATE 
6 months DAPT 
vs 
12 months DAPT 
after DES 
in ACS patients 
no significant difference 
in MACE 
6-months DAPT 
non-inferior 
trial too small 
CVD REAL 2 
SGLT2i 
vs 
other antiglycaemic drugs 
type 2 diabetes 
lower event rates for 
death, HF, MI, stroke 
wide ranging benefits 
of SGLT2i 
observational study 
selection biases likely 
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Figure 1 Primary efficacy Endpoint MACE from the ODYSSEY OUTCOMES trial 
 
 
 
Figure 1 Primary efficacy endpoint MACE from the ODYSSEY OUTCOMES trial 
Figure 1 CAPTION: Kaplan-Meier plot of cumulative MACE events (CHD death, non-fatal 
MI, ischemic stroke, or unstable angina requiring hospitalization) by treatment group. The 
figure reveals a significant time-treatment interaction whereby all the benefit appears to kick 
in after one year’s treatment. This departure from the proportional hazards assumption calls 
into question whether a hazard ratio is the best overall summary of the treatment effect. 
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Figure 2 Hazard ratios for MACE outcome both overall and for key subgroups in the SECURE-PCI trial 
 
 
Figure 2 CAPTION: Forest plot showing the hazard ratio for MACE in all patients (HR 0.88, 
95% CI 0.69-1.11) and in patients undergoing PCI (HR 0.72, 95% CI 0.54-0.96) or not (HR 
1.36, 95% CI 0.89-2.09). This was the only significant interaction (P=0.02) among several 
exploratory subgroup analyses. But undergoing PCI is an improper subgroup being unknown 
at the time of randomization. Further PCI v no PCI comparisons are presented for STEMI 
(interaction P=0.04) and NSTEMI (interaction P=0.13) patients. Such multiple subgroup 
analyses require a cautious interpretation. 
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Figure 3: Landmark analysis of MACE at 6 months after the index procedure in the SMART-DATE trial 
 
 
 
Figure 3 CAPTION: Kaplan-Meier plot of cumulative MACE events over time by treatment 
group with landmark analysis at 6 months in the SMART-DATE trial. Since everyone gets 
DAPT for the first six months, only MACE events occurring after 6 months are really 
relevant to the treatment comparison. The MACE rate after 6 months is somewhat higher in 
the 6-month DAPT group: hazard ratio 1.69 (95% CI 0.97 to 2.94), P=0.07. The CI is very 
wide since the numbers of MACE events between 6 months and 18 months are relatively 
small. We are now close to significant inferiority of the 6-month DAPT arm, and any claim 
of non-inferiority is clearly ruled out. 
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Figure 4 Forest plots from random-effects meta-analyses of outcomes in the CVD-REAL 2 study 
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Figure 4 CAPTION: Forest plots from random-effects meta-analyses showing superiority of 
SGLT2i v oGLD for the outcomes of all-cause death (P<0.001), hospitalization for heart 
failure (P<0.001), myocardial infarction (P<0.001), and stroke (P<0.001) in the CVD-REAL 
2 study. Heterogeneity tests were statistically significant for all-cause death (P<0.001),  
hospitalisation for heart failure (P<0.001) and stroke (P=0.029). The associations were 
generally weaker in Korea, which contributed 70% of the data. Such non-randomized 
treatment comparisons require a cautious interpretation because of the potential for selection 
bias. 
 
 
